{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T04:17:18Z","timestamp":1768709838175,"version":"3.49.0"},"reference-count":17,"publisher":"BMJ","issue":"1","funder":[{"DOI":"10.13039\/501100002996","name":"Dutch Heart Foundation","doi-asserted-by":"crossref","award":["Senior Clinical Scientist: 2020T058"],"award-info":[{"award-number":["Senior Clinical Scientist: 2020T058"]}],"id":[{"id":"10.13039\/501100002996","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2020,12,10]]},"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:p>We present a 51-year-old Caucasian woman, with a medical history of systemic lupus erythematosus (SLE) who had dyspnoea at exertion. The SLE was clinically quiescent but serologically active. Echocardiography showed preserved left ventricular (LV) systolic function, pseudonormal mitral inflow pattern (diastolic dysfunction grade III), absence of wall motion abnormalities and elevated E\/e\u2019 at exercise. An exercise right heart catheterisation was performed, confirming the diagnosis of heart failure with preserved ejection fraction (HFpEF). In the absence of other possible causes, we assumed that HFpEF was mediated by systemic inflammation secondary to SLE. Based on the Paulus\u2019 paradigm, that systemic inflammation may lead to diastolic dysfunction, we decided to add belimumab (a biological agent against soluble B-lymphocyte stimulator protein). After 16\u2009weeks of treatment, patient reported an improved condition. Also, cardiopulmonary exercise test and echocardiography results improved, confirming resolution of the underlying LV diastolic dysfunction. This case supports the idea that targeting inflammation has therapeutic potential in a subset of HFpEF-patients.<\/jats:p>","DOI":"10.1136\/bcr-2020-237549","type":"journal-article","created":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T11:40:59Z","timestamp":1610710859000},"page":"e237549","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":10,"title":["Clinical improvement of cardiac function in a patient with systemic lupus erythematosus and heart failure with preserved ejection fraction treated with belimumab"],"prefix":"10.1136","volume":"14","author":[{"given":"Milad","family":"Baniaamam","sequence":"first","affiliation":[{"name":"Rheumatology, VU University Medical Center, Amsterdam, The Netherlands"},{"name":"Rheumatology, Reade, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre E","family":"Voskuyl","sequence":"additional","affiliation":[{"name":"Rheumatology, VU University Medical Center, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael T","family":"Nurmohamed","sequence":"additional","affiliation":[{"name":"Rheumatology, VU University Medical Center, Amsterdam, The Netherlands"},{"name":"Rheumatology, Reade, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M Louis","family":"Handoko","sequence":"additional","affiliation":[{"name":"Cardiology, VU University Medical Center, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2021,1,15]]},"reference":[{"key":"2025082800110968000_14.1.e237549.1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.021884"},{"key":"2025082800110968000_14.1.e237549.2","doi-asserted-by":"publisher","DOI":"10.1093\/eurjhf\/hfq121"},{"key":"2025082800110968000_14.1.e237549.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2013.03.013"},{"key":"2025082800110968000_14.1.e237549.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.02.092"},{"key":"2025082800110968000_14.1.e237549.5","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1080\/14712598.2018.1462794","article-title":"The effect of biological DMARDs on the risk of congestive heart failure in rheumatoid arthritis: a systematic review","volume":"18","author":"Baniaamam","year":"2018","journal-title":"Expert Opin Biol Ther"},{"key":"2025082800110968000_14.1.e237549.6","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200110)44:10<2331::AID-ART395>3.0.CO;2-I"},{"key":"2025082800110968000_14.1.e237549.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61354-2"},{"key":"2025082800110968000_14.1.e237549.8","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-013-2320-5"},{"key":"2025082800110968000_14.1.e237549.9","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1161\/CIRCULATIONAHA.118.034646","article-title":"A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction","volume":"138","author":"Reddy","year":"2018","journal-title":"Circulation"},{"key":"2025082800110968000_14.1.e237549.10","doi-asserted-by":"publisher","DOI":"10.1007\/s12471-016-0811-0"},{"key":"2025082800110968000_14.1.e237549.11","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.090043"},{"key":"2025082800110968000_14.1.e237549.12","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1080\/AC.66.2.2071246","article-title":"Heart structure and function in patients with generalized autoimmune diseases: echocardiography with tissue Doppler study","volume":"66","author":"Plazak","year":"2011","journal-title":"Acta Cardiol"},{"key":"2025082800110968000_14.1.e237549.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2013.08.047"},{"key":"2025082800110968000_14.1.e237549.14","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1002\/clc.22719","article-title":"Interleukin-1 blockade in heart failure with preserved ejection fraction: rationale and design of the diastolic heart failure Anakinra response trial 2 (D-HART2)","volume":"40","author":"Van Tassell","year":"2017","journal-title":"Clin Cardiol"},{"key":"2025082800110968000_14.1.e237549.15","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/656340"},{"key":"2025082800110968000_14.1.e237549.16","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.731877"},{"key":"2025082800110968000_14.1.e237549.17","doi-asserted-by":"crossref","first-page":"168","DOI":"10.5830\/CVJA-2014-036","article-title":"Infliximab, an anti-TNF-alpha agent, improves left atrial abnormalities in patients with rheumatoid arthritis: preliminary results","volume":"25","author":"\u00c7etin","year":"2014","journal-title":"Cardiovasc J Afr"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2020-237549","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T07:11:24Z","timestamp":1756365084000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2020-237549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,1,15]]},"published-print":{"date-parts":[[2021,1]]}},"alternative-id":["10.1136\/bcr-2020-237549"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2020-237549","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1]]}}}